Effect of amitriptyline on the thyrotropin response to thyrotropin-releasing hormone in endogenous depression

Krog-Meyer, I; Kirkegaard, C.; Kijne, Birgit; Lumholtz, Bo; Smith, Eli; Lykke-Olesen, Lise; Bjørum, N.

doi:10.1016/0165-1781(85)90050-2

Cited by 13 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, a blunted thyrotropin response (TSH) to thyrotropin-releasing hormone (TRH) stimulation has consistently been observed in 25-40% of depressives (Kirkegaard, 1981;Winokur et al, 1983). More recently, Kirkegaard (1981) and Krog-Meyer et al (1985) reported the relationship between long-term treatment outcome and the change in TSH response after repeated TRH testing. In this context, the TRH test may represent a unique 'biological marker' for assessing treatment course in TRD.…”

Section: Defining Treatment-resistant Depressionmentioning

confidence: 99%

Treatment-resistant depression: additional perspectives

Rosenzweig

Amsterdam

1992

J Psychopharmacol

View full text Add to dashboard Cite

Treatment-resistant depression (TRD) is usually thought to characterize -10-15% of patients who are refractory to all conventional antidepressant therapy. However, in its broadest definition, TRD occurs across a spectrum of severity and is not an uncommon clinical problem, defining a sizeable portion of patients with mood disorders. Although the majority of treatment outcome studies report response rates to antidepressants in the 60-70% range, this figure should not be viewed as indicating the rate of remission, but rather an estimate of improvement from minimal response to complete remission. Thus, while as many as 60% of depressed patients may have some degree of response to antidepressant treatment, only ~ 25-30% of patients will achieve clinical remission. Therefore, estimates of response rate can hide the fact that most patients who are described as 'improved' with pharmacotherapy actually have a form of partial TRD. In this framework, a more realistic view of the TRD syndrome should encompass a broad spectrum of cases ranging from partial to complete drug resistance. It is in this context that we view this timely review on TRD by Malizia and Bridges.

show abstract

Section: Defining Treatment-resistant Depressionmentioning

confidence: 99%

Treatment-resistant depression: additional perspectives

Rosenzweig

Amsterdam

1992

J Psychopharmacol

View full text Add to dashboard Cite

show abstract

The influence of 4–week treatment with sertraline on the combined T3/TRH test in depressed patients

Schüle

Baghai

Alajbegovic

et al. 2005

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

In the present study, the influence of a 4-week treatment with sertraline on the regulation of hypothalamic-pituitary-thyroid (HPT) axis activity in depression was investigated, in particular the impact of sertraline on the thyroid receptor (TR)-mediated negative feedback control as measured by the combined T3/TRH test. In 20 drug-free patients (8 men, 12 women) suffering from a major depressive episode according to DSM-IV criteria the single TRH-stimulation test (administration of 200 microg TRH at 09:00h) was carried out followed by a combined T3/TRH test (pre-treatment with 40 microg 3,5,3'-triiodothyronine [T3] the night before; administration of 200 microg TRH at 09:00h the next day). After 4 weeks of treatment with sertraline at a standard dosage of 50 mg/day, both the single TRH test and the combined T3/TRH test were repeated in the depressed patients. Using repeated-measures ANOVA for statistical analysis, antidepressant therapy with sertraline did not have any significant impact on the TRH-induced TSH and prolactin stimulation (deltaTSH, deltaPRL) during the single TRH test nor during the combined T3/TRH test, neither in responders (n = 10) nor in non-responders (n = 10). Moreover, the percentage suppression of TRH-induced TSH stimulation (deltaTSH) after pre-treatment with 40 microg T3 was comparable before (-61.07%) and after the 4-week treatment with sertraline (-58.92%). Apparently, the therapeutic efficacy of antidepressants such as sertraline is not related to the regulation of HPT axis activity in depressed patients.

show abstract